Mevastatin (Synonyms: Compactin; ML236B)

Name: Mevastatin
Brand: MedChemExpress
SKU: HY-17408
Rating: 5.0 (7 reviews)

Cat. No.: HY-17408 Purity: 99.46%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G₀/G₁ phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment.

For research use only. We do not sell to patients.

CAS No. : 73573-88-3

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	Get quote
5 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 7 publication(s) in Google Scholar

Other Forms of Mevastatin:

Mevastatin (Standard) Get quote

7 Publications Citing Use of MCE Mevastatin

•Eur Res J. 2018;4(4):266-274.

Cell Proliferation/Viability Assay

: Mevastatin purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2020 Jan 13;11(1):25. [Abstract]; Cell proliferation ability was evaluated using the MTS assay in SKOV3 cells treated as indicated (EV, empty vector; SIK2, expression vector encoding SIK2; C75, FASN inhibitor, 25 μM for 24 h; Mevastatin, HMGCR inhibitor, 1 μM for 24 h).

: Mevastatin purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2020 Sep;20(3):2855-2869. [Abstract]; Western blotting showing the location of mSREBP, SCD1 and β‑catenin in KYSE-150 cells treated with or without Mevastatin (10 µM) for 24 h.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Antibiotic Isoform Specific Products:

View All Isoforms

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

HMG-CoA reductase^[1]^[2]
Apoptosis^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
DLD-1	IC₅₀	3.2 μM Compound: 26	Cytotoxicity in human DLD-1 cells expressing APC mutant assessed as reduction in cell viability incubated for 96 hrs by Cell Titer-Glo assay Cytotoxicity in human DLD-1 cells expressing APC mutant assessed as reduction in cell viability incubated for 96 hrs by Cell Titer-Glo assay	[PMID: 33445154]
HCT-116	IC₅₀	18.6 μM Compound: 26	Cytotoxicity in human HCT-116 cells expressing wild type APC assessed as reduction in cell viability incubated for 96 hrs by Cell Titer-Glo assay Cytotoxicity in human HCT-116 cells expressing wild type APC assessed as reduction in cell viability incubated for 96 hrs by Cell Titer-Glo assay	[PMID: 33445154]
HEK293	IC₅₀	159 μM Compound: 27	Inhibition of human TASK3 expressed in HEK293 cells by Ti+ flux assay Inhibition of human TASK3 expressed in HEK293 cells by Ti+ flux assay	[PMID: 31260312]

In Vitro

Mevastatin (0-128 μM; 5 days; Caco-2 cells) treatment causes a dose-dependent decrease in cell number^[1].
Mevastatin (32-128 μM; 24-72 hours; Caco-2 cells) treatment causes an early G0/G1 phase and a late G2/M phase cell cyclr arrest^[1].
Mevastatin (32-128 μM; 72 hours; Caco-2 cells) treatment causes a down-regulation of cyclin-dependent kinases (cdk) 4 and cdk 6 as well as cyclin D1, while cdk 2 and cyclin E protein levels remained unchanged. Cell cycle inhibitors p21 and p27 are significantly upregulated by Mevastatin^[1].
Mevastatin (16-256 μM; Caco-2 cells) treatment induces apoptosis in a dose-dependent manner^[1].
Treatment of Neuro2a cells with mevastatin for 24 hours induced neurite outgrowth associated with up-regulation of the neuronal marker protein NeuN. Mevastatin triggers phosphorylation of the key kinases epidermal growth factor receptor (EGFR), ERK1/2, and Akt/protein kinase B. Inhibition of EGFR, PI3K, and the mitogen-activated protein kinase cascade blocks Mevastatin-induced neurite outgrowth^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	Caco-2 cells
Concentration:	0 µM, 8 µM, 16 µM, 32 µM, 64 µM, 128 µM
Incubation Time:	5 days
Result:	Caused a dose-dependent decrease in cell number.

Cell Cycle Analysis^[2]

Cell Line:	Caco-2 cells
Concentration:	32 µM, 64 µM, 128 µM
Incubation Time:	24 hours, 48 hours, 72 hours
Result:	Caused a dose-dependent increase of cells in G0/G1 and G2/M phases of the cell cycle.

Western Blot Analysis^[2]

Cell Line:	Caco-2 cells
Concentration:	32 µM, 64 µM, 128 µM
Incubation Time:	72 hours
Result:	Resulted in a down-regulation of cyclin-dependent kinases (cdk) 4 and cdk 6 as well as cyclin D1.

In Vivo

Mevastatin (2-20 mg/kg; delivered via ALZET miniosmotic pumps; daily; for 7, 14, or 28 days; wild-type 129-SV/eVTAcBr male mice and eNOS-deficient male mice) treatment increases levels of endothelial nitric oxide synthase (eNOS) mRNA and protein, reduces infarct size, and improves neurological deficits in a dose- and time-dependent manner^[2].
The topical infusion of Mevastatin (2.5 pmol/hr) increases bone mass (MRL/MpJ mouse) of isografted bone by increasing bone turnover and, at least in part, by promoting the expression of bone morphogenetic protein-2 (BMP-2) mRNA and receptor activator of NF-κB ligand (RANKL) mRNA^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wild-type 129-SV/eVTAcBr male mice and eNOS-deficient male mice (18-22 g) with the filament model^[2]
Dosage:	2 mg/kg or 20 mg/kg
Administration:	Delivered via 7- or 14-day ALZET miniosmotic pumps implanted subcutaneously; daily; for 7, 14, or 28 days
Result:	Increased levels of endothelial nitric oxide synthase (eNOS) mRNA and protein, reduced infarct size, and improved neurological deficits in a dose- and time-dependent manner.

Molecular Weight

390.51

Formula

C₂₃H₃₄O₅

CAS No.

73573-88-3

Appearance

Solid

Color

White to off-white

SMILES

CC[C@H](C)C(O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(O3)=O)[C@@]12[H])=O

Structure Classification

Others

Initial Source

Microorganisms

Penicillium citrinum

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 200 mg/mL (512.15 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.5608 mL	12.8038 mL	25.6075 mL
5 mM	0.5122 mL	2.5608 mL	5.1215 mL
10 mM	0.2561 mL	1.2804 mL	2.5608 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.46%

Select Batch:

Data Sheet (284 KB) SDS (393 KB)

COA (255 KB) LCMS (87 KB)

Handling Instructions (2659 KB)

References

[1]. Wächtershäuser A, et al. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis. 2001 Jul;22(7):1061-7. [Content Brief]

[2]. Amin-Hanjani S, Stagliano NE, Yamada M, et al. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke. 2001 Apr;32(4):980-6. [Content Brief]

[3]. Sugazaki M, Hirotani H, Echigo S, et al. Effects of mevastatin on grafted bone in MRL/MpJ mice. Connect Tissue Res. 2010 Apr;51(2):105-12. [Content Brief]

[4]. Evangelopoulos ME, Weis J, Krüttgen A. Mevastatin-induced neurite outgrowth of neuroblastoma cells via activation of EGFR. J Neurosci Res. 2009 Jul;87(9):2138-44. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.5608 mL	12.8038 mL	25.6075 mL	64.0188 mL
	5 mM	0.5122 mL	2.5608 mL	5.1215 mL	12.8038 mL
	10 mM	0.2561 mL	1.2804 mL	2.5608 mL	6.4019 mL
	15 mM	0.1707 mL	0.8536 mL	1.7072 mL	4.2679 mL
	20 mM	0.1280 mL	0.6402 mL	1.2804 mL	3.2009 mL
	25 mM	0.1024 mL	0.5122 mL	1.0243 mL	2.5608 mL
	30 mM	0.0854 mL	0.4268 mL	0.8536 mL	2.1340 mL
	40 mM	0.0640 mL	0.3201 mL	0.6402 mL	1.6005 mL
	50 mM	0.0512 mL	0.2561 mL	0.5122 mL	1.2804 mL
	60 mM	0.0427 mL	0.2134 mL	0.4268 mL	1.0670 mL
	80 mM	0.0320 mL	0.1600 mL	0.3201 mL	0.8002 mL
	100 mM	0.0256 mL	0.1280 mL	0.2561 mL	0.6402 mL

Mevastatin Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Mevastatin (Synonyms: Compactin; ML236B)

Customer Review

Other Forms of Mevastatin:

Mevastatin Related Antibodies

7 Publications Citing Use of MCE Mevastatin

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Antibiotic Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Mevastatin Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Mevastatin Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report